Biotech Values

[iwfal]

FGEN AKBA Moutons post doesn’t mention that AKBA missed its non-inferiority vs a black box arm. Whereas FGEN made their non-inferiority vs **placebo**. So it’s possible there is carry over from Vada to Roxa, but it doesn’t seem highly likely.

(Note: I’m sure Mouton knows the difference between Roxa trials and Vada, but just didn’t recap. But others may not know that difference)